Lead researcher
Dr Michael Michael, Associate Professor Bryan Burmeister, Dr Andrew Wirth
Institution
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre
Years funded
2005-2006
A significant proportion of lung cancer patients can not be treated with six weeks of curative chemoradiotherapy. However, treatment with either modality alone is associated with poor results. This national study will compare two regimens of lower dose chemoradiation that have been shown to provide promising results. Patients will be assessed during and after therapy for side effects, quality of life and response to treatment. The best regimen, based on these assessments, will then be compared to the standard of radiation alone in a later larger study.